BACKGROUND: The only pharmacological treatment with proven cost-effectiveness in reducing acute ischemic stroke (AIS) associated disability is intravenous thrombolysis with recombinant tissue plasminogen activator but it's utilization rate is still low in most of the world. We estimated the minim...
Selecciona los documentos para visualizarlos
Nombre del archivo | Ver recurso |
---|